Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma

Hideaki Shiraishi; Yutaka Fujiwara; Takanori Kakuya; Koji Tsuta; Noriko Motoi; Nami Miura; Yukio Watabe; Shun Ichi Watanabe; Rintaro Noro; Kengo Nagashima; Wilber Huang; Tesshi Yamada; Hisao Asamura; Yuichiro Ohe; Kazufumi Honda

doi:10.2217/bmm-2017-0150

Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma

Hideaki Shiraishi, Yutaka Fujiwara, Takanori Kakuya, Koji Tsuta, Noriko Motoi, Nami Miura, Yukio Watabe, Shun Ichi Watanabe, Rintaro Noro, Kengo Nagashima, Wilber Huang, Tesshi Yamada, Hisao Asamura, Yuichiro Ohe, Kazufumi Honda

Department of Surgery (General Thoracic Surgery)

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

Aim: Although several clinical trials demonstrated the benefits of platinum-combination adjuvant chemotherapy for stage II-IIIA lung adenocarcinoma, predictive biomarkers for the efficacy of such therapy have not yet been identified. We evaluated protein overexpression of actinin-4 as a predictive biomarker of the efficacy of adjuvant chemotherapy in resected lung adenocarcinoma. Materials & methods: We measured actinin-4 protein levels in patients with completely resected stage II-IIIA lung adenocarcinoma using immunohistochemistry and then retrospectively compared survival between adjuvant chemotherapy and observation groups. Results: A total of 148 eligible patients were classified into actinin-4 positive or negative cases by immunohistochemistry. In the former, patients with adjuvant chemotherapy survived significantly longer than those with observation (hazard ratio [HR]: 0.307; p = 0.028). But, no significant survival benefit was noted with adjuvant chemotherapy (HR: 0.926; p = 0.876) in the latter. Conclusion: This marker could predict the efficacy of adjuvant chemotherapy for resected lung adenocarcinoma patients.

Original language	English
Pages (from-to)	721-731
Number of pages	11
Journal	Biomarkers in Medicine
Volume	11
Issue number	9
DOIs	https://doi.org/10.2217/bmm-2017-0150
Publication status	Published - 2017 Sept

Keywords

actinin-4 (ACTN4)
adjuvant chemotherapy
predictive biomarker

ASJC Scopus subject areas

Drug Discovery
Clinical Biochemistry
Biochemistry, medical

Access to Document

10.2217/bmm-2017-0150

Cite this

Shiraishi, H., Fujiwara, Y., Kakuya, T., Tsuta, K., Motoi, N., Miura, N., Watabe, Y., Watanabe, S. I., Noro, R., Nagashima, K., Huang, W., Yamada, T., Asamura, H., Ohe, Y., & Honda, K. (2017). Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma. Biomarkers in Medicine, 11(9), 721-731. https://doi.org/10.2217/bmm-2017-0150

Shiraishi, H, Fujiwara, Y, Kakuya, T, Tsuta, K, Motoi, N, Miura, N, Watabe, Y, Watanabe, SI, Noro, R, Nagashima, K, Huang, W, Yamada, T, Asamura, H, Ohe, Y & Honda, K 2017, 'Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma', Biomarkers in Medicine, vol. 11, no. 9, pp. 721-731. https://doi.org/10.2217/bmm-2017-0150

@article{7dd9a84ce9884b49875ca0833714824e,

title = "Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma",

abstract = "Aim: Although several clinical trials demonstrated the benefits of platinum-combination adjuvant chemotherapy for stage II-IIIA lung adenocarcinoma, predictive biomarkers for the efficacy of such therapy have not yet been identified. We evaluated protein overexpression of actinin-4 as a predictive biomarker of the efficacy of adjuvant chemotherapy in resected lung adenocarcinoma. Materials & methods: We measured actinin-4 protein levels in patients with completely resected stage II-IIIA lung adenocarcinoma using immunohistochemistry and then retrospectively compared survival between adjuvant chemotherapy and observation groups. Results: A total of 148 eligible patients were classified into actinin-4 positive or negative cases by immunohistochemistry. In the former, patients with adjuvant chemotherapy survived significantly longer than those with observation (hazard ratio [HR]: 0.307; p = 0.028). But, no significant survival benefit was noted with adjuvant chemotherapy (HR: 0.926; p = 0.876) in the latter. Conclusion: This marker could predict the efficacy of adjuvant chemotherapy for resected lung adenocarcinoma patients.",

keywords = "actinin-4 (ACTN4), adjuvant chemotherapy, predictive biomarker",

author = "Hideaki Shiraishi and Yutaka Fujiwara and Takanori Kakuya and Koji Tsuta and Noriko Motoi and Nami Miura and Yukio Watabe and Watanabe, {Shun Ichi} and Rintaro Noro and Kengo Nagashima and Wilber Huang and Tesshi Yamada and Hisao Asamura and Yuichiro Ohe and Kazufumi Honda",

note = "Funding Information: This work was supported by the Japan Agency for Medical Research and Development (AMED) Practical Research for Innovation Cancer Control (15ck0106101h0002, K Honda), the AMED Project for Cancer Research And Therapeutic Evolution (P-CREATE) (17cm0106403h0002, K Honda), AMED CREST (17gm0710010h0104 and 17gm0710013h0304, K Honda), a Grant-in Aid for Scientific Research (B) (16H05547), and by the Ministry of Education, Culture, Sports, Science and Technology (METX) of Japan (16K15833, K H.). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2017 Kazufumi Honda.",

year = "2017",

month = sep,

doi = "10.2217/bmm-2017-0150",

language = "English",

volume = "11",

pages = "721--731",

journal = "Biomarkers in Medicine",

issn = "1752-0363",

publisher = "Future Medicine Ltd.",

number = "9",

}

TY - JOUR

T1 - Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma

AU - Shiraishi, Hideaki

AU - Fujiwara, Yutaka

AU - Kakuya, Takanori

AU - Tsuta, Koji

AU - Motoi, Noriko

AU - Miura, Nami

AU - Watabe, Yukio

AU - Watanabe, Shun Ichi

AU - Noro, Rintaro

AU - Nagashima, Kengo

AU - Huang, Wilber

AU - Yamada, Tesshi

AU - Asamura, Hisao

AU - Ohe, Yuichiro

AU - Honda, Kazufumi

N1 - Funding Information: This work was supported by the Japan Agency for Medical Research and Development (AMED) Practical Research for Innovation Cancer Control (15ck0106101h0002, K Honda), the AMED Project for Cancer Research And Therapeutic Evolution (P-CREATE) (17cm0106403h0002, K Honda), AMED CREST (17gm0710010h0104 and 17gm0710013h0304, K Honda), a Grant-in Aid for Scientific Research (B) (16H05547), and by the Ministry of Education, Culture, Sports, Science and Technology (METX) of Japan (16K15833, K H.). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: © 2017 Kazufumi Honda.

PY - 2017/9

Y1 - 2017/9

N2 - Aim: Although several clinical trials demonstrated the benefits of platinum-combination adjuvant chemotherapy for stage II-IIIA lung adenocarcinoma, predictive biomarkers for the efficacy of such therapy have not yet been identified. We evaluated protein overexpression of actinin-4 as a predictive biomarker of the efficacy of adjuvant chemotherapy in resected lung adenocarcinoma. Materials & methods: We measured actinin-4 protein levels in patients with completely resected stage II-IIIA lung adenocarcinoma using immunohistochemistry and then retrospectively compared survival between adjuvant chemotherapy and observation groups. Results: A total of 148 eligible patients were classified into actinin-4 positive or negative cases by immunohistochemistry. In the former, patients with adjuvant chemotherapy survived significantly longer than those with observation (hazard ratio [HR]: 0.307; p = 0.028). But, no significant survival benefit was noted with adjuvant chemotherapy (HR: 0.926; p = 0.876) in the latter. Conclusion: This marker could predict the efficacy of adjuvant chemotherapy for resected lung adenocarcinoma patients.

AB - Aim: Although several clinical trials demonstrated the benefits of platinum-combination adjuvant chemotherapy for stage II-IIIA lung adenocarcinoma, predictive biomarkers for the efficacy of such therapy have not yet been identified. We evaluated protein overexpression of actinin-4 as a predictive biomarker of the efficacy of adjuvant chemotherapy in resected lung adenocarcinoma. Materials & methods: We measured actinin-4 protein levels in patients with completely resected stage II-IIIA lung adenocarcinoma using immunohistochemistry and then retrospectively compared survival between adjuvant chemotherapy and observation groups. Results: A total of 148 eligible patients were classified into actinin-4 positive or negative cases by immunohistochemistry. In the former, patients with adjuvant chemotherapy survived significantly longer than those with observation (hazard ratio [HR]: 0.307; p = 0.028). But, no significant survival benefit was noted with adjuvant chemotherapy (HR: 0.926; p = 0.876) in the latter. Conclusion: This marker could predict the efficacy of adjuvant chemotherapy for resected lung adenocarcinoma patients.

KW - actinin-4 (ACTN4)

KW - adjuvant chemotherapy

KW - predictive biomarker

UR - http://www.scopus.com/inward/record.url?scp=85029783329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029783329&partnerID=8YFLogxK

U2 - 10.2217/bmm-2017-0150

DO - 10.2217/bmm-2017-0150

M3 - Article

C2 - 28658966

AN - SCOPUS:85029783329

SN - 1752-0363

VL - 11

SP - 721

EP - 731

JO - Biomarkers in Medicine

JF - Biomarkers in Medicine

IS - 9

ER -

Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this